A federal investigation into a paper on prostate cancer has now led to a retraction. In an unusual twist, it happened following a request from the animal rights group People for the Ethical Treatment of Animals (PETA).
In January, the Office of Research Integrity reported that corresponding author Dong Xiao “intentionally fabricated data” in an Oncotarget study of how a steroid inhibits the growth of prostate cancer. Xiao, a former cancer researcher at the University of Pittsburgh, claimed that he had tumor data from more mice than he did, and falsified several figures.
In July, after no sign of the retraction, a researcher at PETA followed up with the journal, Oncotarget, on behalf of the organization “and our more than 3 million members and supporters to request the immediate retraction.”
Last month, they received a reply from the publisher, which they forwarded to us:
Continue reading Prostate cancer paper flagged by ORI is retracted following PETA prompt



To one reader of a paper on a nerve cancer, the researchers, based at a hospital in China, seemed to have found a very large number of cases of a rare cancer to study. That observation triggered an investigation into the paper that led to its retraction — and the concern that the authors in the paper never did the research at all.

A 2010 paper on plant fungus has been retracted after a comment on PubPeer revealed that a study image had been flipped over and reused to represent two different treatments.
A paper containing data fudged by former University of California San Francisco grad student Peter Littlefield has been corrected. We knew that this was coming — last month, 